Screener / SEC EDGAR /CIK 0001609550 /10-K filed Feb 13, 2026, compared with Feb 10, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

Inspire Medical Systems, Inc. INSP

Compare with peers Embed
Earnings releases

Latest results release: Nov 2, 2026

8-K item 2.02, exhibit 99

What INSP's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

In its release of Nov 2, 2026, INSP reported −$0.84 per share under GAAP and $0.14 on its own adjusted basis.

GAAP EPS $-0.12, release Aug 4, 2025: Loss per share was $0.12 in the second quarter of 2025. Adjusted EPS $0.45, release Aug 4, 2025: Adjusted diluted earnings per share was $0.45 2025-08 GAAP EPS $0.34, release Nov 3, 2025: Income per share was $0.34 in the third quarter of 2025. Adjusted EPS $0.38, release Nov 3, 2025: Adjusted diluted earnings per share was $0.38 +12% 2025-11 GAAP EPS $4.66, release Feb 11, 2026: Net income per diluted share was $4.66 and adjusted net income per diluted share was $1.65. Adjusted EPS $1.65, release Feb 11, 2026: Net income per diluted share was $4.66 and adjusted net income per diluted share was $1.65. -65% 2026-02 GAAP EPS $-0.39, release May 4, 2026: Diluted EPS was $(0.39) and adjusted diluted EPS was $0.10. Adjusted EPS $0.10, release May 4, 2026: Diluted EPS was $(0.39) and adjusted diluted EPS was $0.10. 2026-05 GAAP EPS $0.01, release Aug 3, 2026: Diluted EPS was $0.01 and adjusted diluted EPS was $0.14. Adjusted EPS $0.14, release Aug 3, 2026: Diluted EPS was $0.01 and adjusted diluted EPS was $0.14. +1300% 2026-08 GAAP EPS $-0.84, release Nov 2, 2026: Third quarter diluted EPS of $(0.84) Adjusted EPS $0.14, release Nov 2, 2026: Third quarter diluted EPS of $(0.84); adjusted diluted EPS of $0.14 2026-11
GAAP EPSAdjusted EPS, as the company defines itThe figure on top is how far adjusted is from GAAP. Click a bar for the sentence.
ReleaseGAAP EPSAdjusted EPSGap
Nov 2, 2026 -0.84 0.14 –
Aug 3, 2026 0.01 0.14 +1300%
May 4, 2026 -0.39 0.10 –
Feb 11, 2026 4.66 1.65 -65%
Nov 3, 2025 0.34 0.38 +12%
Aug 4, 2025 -0.12 0.45 –
The company's words, latest release
Third quarter diluted EPS of $(0.84) release
Third quarter diluted EPS of $(0.84); adjusted diluted EPS of $0.14 release

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 2, 2026 · EX-99.1

Inspire Medical Systems, Inc. Announces Third Quarter 2026

Open on SEC

• AMA CPT® Editorial Panel approved new Category I CPT codes for single lead hypoglossal nerve stimulation, including Inspire V, set to take effect January 1, 2028

- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the Company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended September 30, 2026.

“We are pleased to have delivered sequential growth in the third quarter, with U.S. performance coming in ahead of our expectations. Results suggest that, despite some lingering headwinds, there is greater comfort among implanting physicians with the current coding dynamic. We will stay disciplined in our education initiatives and focused on executing our strategic priorities as we finish out 2026 and plan for a return to growth in 2027,” said Tim Herbert, Chairman and CEO of Inspire Medical Systems.

“Looking further ahead, we were also pleased with the AMA Editorial Panel’s September approval of a new CPT® code for single lead HGNS devices, including the Inspire V system. When this takes effect in January 2028, a dedicated code set will give physicians and hospitals enhanced clarity around coding and reimbursement and, in turn, further enable patient access to Inspire therapy. With that progress, and the investment capacity we’re redirecting into high- impact revenue growth initiatives through Project Horizon, we believe we are positioned well for growth in the years ahead.”

Third Quarter 2026 Financial Results (Third Quarter 2026 compared to Third Quarter 2025)

• Revenue decreased 7.9% to $206.7 million, driven primarily by a decline in U.S. revenue. The U.S. revenue decline was primarily driven by the adverse impacts of coding and reimbursement challenges.

• Gross margin increased 20 bps to 86.0%, primarily due to increased sales mix of the Inspire V system, which has a higher gross margin than the Inspire IV system.

• Operating expenses increased $23.5 million, or 12.8%, to $206.6 million, primarily due to $24.1 million of restructuring charges, legal settlement expense of $7.0 million, and higher legal fees, partially offset by lower marketing expenses and lower stock-based compensation expense.

• Operating loss was $28.7 million, and operating margin was (13.9)%. Adjusted operating income was $1.9 million, and adjusted operating margin was 0.9%.

• The effective tax rate was 2.5% compared to 26.7%. The decrease in the effective tax rate was primarily driven by the current period pre-tax loss and discrete tax charges related to restructuring. For the three months ended September 30, 2025, the Company maintained a full valuation allowance against federal and state deferred tax assets, which was subsequently released at December 31, 2025.

• Net cash provided by operating activities for the three months ended September 30, 2026 was $46.4 million, compared to $68.5 million in the prior year period. The change was primarily driven by lower net earnings and lower collections on receivables due to the third quarter 2025 cash recovery following temporary issues with the implementation of a new invoice portal and delivery process in the second quarter of 2025.

• As of September 30, 2026, cash, cash equivalents, and investments increased $48.5 million to $453.1 million as compared to December 31, 2025.

The Company is narrowing its previously announced revenue outlook to be in the range of $850 million to $860 million, compared to the previous range of $835 million to $875 million. Additionally, the Company now expects adjusted operating margin to be in the range of 4.5% to 5.5%, diluted EPS to be in the range of $(0.36) to $(0.10) and adjusted diluted EPS to be in the range of $1.20 to $1.40.

The Company’s outlook assumes an effective tax rate of approximately 120% to 175% and an adjusted effective tax rate of 33% to 34%, estimated weighted average diluted shares outstanding of approximately 28.9 million, and capital expenditures between $35 million to $40 million.

The Company's management will host a conference call after market close today, Monday, November 2, 2026, at 5:00 p.m. Eastern Time to discuss these results and answer questions.

https://register-conf.media- server.com/register/BI4b0290b4bb464cecaa0a2b420ca13a02 .

A live webcast of the event can be accessed on https://edge.media- server.com/mmc/p/d84s2zzb/ . A replay of the webcast will be available on https://investors.inspiresleep.com starting approximately two hours after the event and archived on the site for two weeks.

Inspire Medical Systems is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

This press release includes non-GAAP financial measures, including without limitation, adjusted operating income, adjusted operating margin, adjusted earnings before income taxes, adjusted income tax expense, adjusted effective tax rate, adjusted net earnings, adjusted net earnings per diluted share ("EPS"), adjusted EBITDA, and adjusted EBITDA margin, which differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”).

We define adjusted operating income as operating income or loss adjusted for items that are not indicative of our ongoing operations. Operating income is the most directly comparable GAAP financial measure to adjusted operating income. We define adjusted operating margin in this release as adjusted operating income divided by revenue. Operating margin is the most directly comparable GAAP financial measure to adjusted operating margin. Adjusted earnings before income taxes is defined as earnings before income taxes, adjusted for items that are not

indicative of our ongoing operations. Earnings before income taxes is the most directly comparable GAAP financial measure. Adjusted income tax expense is defined as income tax expense, adjusted for items that are not indicative of our ongoing operations. Adjusted effective tax rate is adjusted income tax expense divided by adjusted earnings before income taxes. Income tax expense is the most directly comparable GAAP financial measure. Adjusted net earnings is defined as net earnings or loss, adjusted for items that are not indicative of our ongoing operations. Net earnings or loss is the most directly comparable GAAP financial measure to adjusted net earnings. Adjusted net earnings per diluted share is calculated as adjusted net earnings divided by the diluted weighted average shares outstanding. Net earnings or loss per diluted share is the most directly comparable GAAP financial measure to adjusted net earnings per diluted share. We define adjusted EBITDA as net earnings or loss, less interest and dividend income, net, plus income tax expense, plus depreciation and amortization, plus stock-based compensation expense, adjusted for items that are not indicative of our ongoing operations. Net earnings or loss is the most directly comparable GAAP financial measure to adjusted EBITDA. We define adjusted EBITDA margin in this release as adjusted EBITDA divided by revenue. Net earnings or loss margin is the most directly comparable GAAP measure to adjusted EBITDA margin. Reconciliations of these non-GAAP financial measures to their most directly comparable GAAP measures are included in this press release.

These non-GAAP financial measures are presented because we believe they are useful indicators of our operating performance and facilitate a more meaningful trend analysis without the distortion of various adjustment items. Management uses these measures principally as measures of our underlying operating performance, trends, and for planning purposes, including the preparation of our annual operating plan and financial projections. We believe these measures are useful to investors as supplemental information and because they are frequently used by analysts, investors, and other interested parties to evaluate companies in our industry. We also believe these non-GAAP financial measures are useful to our management and investors as a measure of comparative operating performance from period to period.

These non-GAAP financial measures should not be considered as an alternative to, or superior to, the most directly comparable GAAP financial measures, as measures of financial performance or cash flows from operations, as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and they should not be construed to imply that our future results will be unaffected by unusual or non-recurring items. In addition, Adjusted EBITDA is not intended to be a measure of cash flow for management’s discretionary use, as it does not reflect certain cash requirements such as tax payments, capital expenditures, and certain other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs, and cash costs to replace assets being depreciated and amortized. In evaluating our non-GAAP financial measures, you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of non-GAAP financial measures should not be construed to imply that our future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on our GAAP results in addition to using non-GAAP financial measures on a supplemental basis. These measures and their definitions are discussed in more detail below and our definition of these non-GAAP financial measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding estimated financial and non-financial impacts from our strategic growth plan (including without limitation , the extent and manner of the use of investments in revenue growth initiatives as well as the time to complete the strategic growth plan) and potential impacts to our business (including potential actions and solutions, such as the new Category I CPT code for Inspire V set to take effect January 1, 2028 and final 2027 Medicare reimbursement payments, as well as timing of these impacts and any related clarity) associated with coding and reimbursement, and our expectations regarding our future growth prospects and full year 2026 financial outlook (including without limitation expectations for the impacts of coding and reimbursement, revenue, expected growth, adjusted operating margin, net earnings or loss per diluted share, adjusted net earnings per diluted share, effective tax rate, adjusted effective tax rate, weighted average diluted shares outstanding and capital expenditures). In some cases, you can identify forward- looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ “future,” “outlook,” “guidance,” ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential,’’ ‘‘continue,’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.

These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward- looking statements. Such risks and uncertainties include, among others: our dependency on our Inspire system for revenues; fluctuations in our financial results and the market price of our common stock; our ability to sustain or increase our profitability and our history of operating losses; commercial success and market acceptance of our Inspire therapy; our ability to achieve and maintain adequate and clear levels of coverage or reimbursement for our Inspire system or any future products we may seek to commercialize; competitive companies, technologies, and pharmaceuticals in our industry; our ability to expand our indications and develop and commercialize additional products and enhancements to our Inspire system; our ability to forecast demand and manage our inventory; our dependence on third-parties; risks related to consolidation in the healthcare industry; our ability to expand, manage, and maintain our direct sales and marketing organization, and to market and sell our Inspire system in markets outside of the United States; our ability to manage our growth; risks related to product liability claims and warranty claims; our ability to address quality issues that may arise with our Inspire system; any failure of key information technology systems, processes, or sites or damage to or inability to access our physical facilities; any violations of anti-bribery, anti-corruption, and anti-money laundering laws; future needs for additional financing; risks related to our tax assets and changes in tax laws; our ability to timely commercialize or obtain regulatory approvals or certifications for our Inspire therapy and system; U.S. Food and Drug Administration (FDA) or other United States or foreign regulatory actions affecting us or the healthcare industry generally; our ability to establish and maintain intellectual property protection for our Inspire therapy and system or avoid claims of infringement; and our strategic growth plan may not achieve our intended outcome.

Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release can be found under the captions “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations“ in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investors page of our website at www.inspiresleep.com. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, unless required by applicable law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.

September 30, 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── Assets Current assets: Cash and cash equivalents $ 190,803 $ 104,813 Investments, short-term 137,168 203,455 Accounts receivable, net of allowance for credit losses of $787 and 104,706 119,692 $1,080, respectively Inventories, net 178,960 145,293 Prepaid expenses and other current 15,988 10,399 assets Total current assets 627,625 583,652 Investments, long-term 125,125 96,330 Property and equipment, net 85,635 97,872 Operating lease right-of-use 22,125 23,532 assets Deferred tax assets 74,196 88,667 Other non-current assets 18,327 17,264 Total assets $ 953,033 $ 907,317 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 38,073 $ 36,565 Accrued expenses 59,265 59,490 Total current liabilities 97,338 96,055 Operating lease liabilities, non-current 28,611 29,998 portion Other non-current liabilities 135 104 Total liabilities 126,084 126,157 Stockholders' equity: Preferred Stock, $0.001 par value; 10,000,000 shares authorized; no — — shares issued and outstanding Common Stock, $0.001 par value; 200,000,000 shares authorized; 28,941,555 and 28,579,015 issued and 29 29 outstanding at September 30, 2026 and December 31, 2025, respectively Additional paid-in capital 1,010,235 927,159 Accumulated other comprehensive (loss) -1,449 464 income Accumulated deficit -181,866 -146,492 Total stockholders' equity 826,949 781,160 Total liabilities and stockholders' $ 953,033 $ 907,317 equity

1 These costs represent legal-related expenses related to (a) a civil investigative demand from the Department of Justice, (b) a patent infringement suit that we filed against Nyxoah S.A. and its wholly-owned subsidiary, Nyxoah, Inc. ("Nyxoah"), and (c) a patent infringement suit brought against us by Nyxoah.

2 Legal settlement expense associated with the proposed settlement of a pixel- tracking class action.

4 Stock-based compensation expense benefit due to share forfeitures related to actions of Project Horizon.

5 The accounting standards codification guidance governing employee stock-based compensation requires that any excess or deficient tax deduction for stock-based compensation be immediately recorded within income tax expense. Employee stock- based compensation activity, including the exercise of stock options, can be unpredictable and can significantly impact our net earnings, net earnings per diluted share, and effective tax rate. These amounts represent the discrete tax expense recorded as excess tax expense for stock-based compensation.

1 These costs represent legal-related expenses related to (a) a civil investigative demand from the Department of Justice, (b) a patent infringement suit that we filed against Nyxoah S.A. and its wholly-owned subsidiary, Nyxoah, Inc. ("Nyxoah"), and (c) a patent infringement suit brought against us by Nyxoah.

2 Legal settlement expense associated with the proposed settlement of a pixel- tracking class action.

4 Stock-based compensation expense benefit due to share forfeitures related to actions of Project Horizon.

5 The accounting standards codification guidance governing employee stock-based compensation requires that any excess or deficient tax deduction for stock-based compensation be immediately recorded within income tax expense. Employee stock- based compensation activity, including the exercise of stock options, can be

unpredictable and can significantly impact our net earnings, net earnings per diluted share, and effective tax rate. These amounts represent the discrete tax expense recorded as excess tax expense for stock-based compensation.

6 Represents accelerated stock-based compensation expense for certain employees who were retirement eligible in accordance with the implementation of changes to the treatment of equity awards under the Inspire Medical Systems, Inc. 2018 Incentive Award Plan upon the holder's death, disability, or retirement.

2 These costs represent legal-related expenses related to (a) a civil investigative demand from the Department of Justice, (b) a patent infringement suit that we filed against Nyxoah S.A. and its wholly-owned subsidiary, Nyxoah, Inc. ("Nyxoah"), and (c) a patent infringement suit brought against us by Nyxoah.

3 Legal settlement expense associated with the proposed settlement of a pixel- tracking class action.

5 Represents a non-cash impairment of a strategic investment. Reconciliation of GAAP Net (Loss) Earnings Margin and Non-GAAP Adjusted EBITDA Margin

1 Net (loss) earnings margin is calculated as net (loss) earnings divided by total revenue.

3 These costs represent legal-related expenses related to (a) a civil investigative demand from the Department of Justice, (b) a patent infringement suit that we filed against Nyxoah S.A. and its wholly-owned subsidiary, Nyxoah, Inc. ("Nyxoah"), and (c) a patent infringement suit brought against us by Nyxoah.

4 Legal settlement expense associated with the proposed settlement of a pixel- tracking class action.

7 Adjusted EBITDA margin is calculated as Adjusted EBITDA divided by total revenue.

Reconciliation of Full Year 2026 Outlook of Estimated Net (Loss) Earnings per Diluted Share

Outlook Full Tax Rate Year 2026 Outlook Full Year 2026 Low Range High Range Low Range High Range Net (loss) per diluted $(0.36) $(0.10) 175.0% 120.0% share Legal fees1 0.31 0.29 Legal 0.18 0.18 settlement2 Restructuring 0.64 0.64 charges3 Share -0.16 -0.16 forfeitures4 Tax impact of stock-based 0.59 0.55 compensation5 Adjusted net earnings per $1.20 $1.40 34.0% 33.0% diluted share

1 These costs represent legal-related expenses related to (a) a civil investigative demand from the Department of Justice, (b) a patent infringement suit that we filed against Nyxoah S.A. and its wholly-owned subsidiary, Nyxoah, Inc. ("Nyxoah"), and (c) a patent infringement suit brought against us by Nyxoah.

2 Legal settlement expense associated with the proposed settlement of a pixel- tracking class action.

4 Stock-based compensation expense benefit due to share forfeitures related to actions of Project Horizon.

5 The accounting standards codification guidance governing employee stock-based compensation requires that any excess or deficient tax deduction for stock-based compensation be immediately recorded within income tax expense. Employee stock- based compensation activity, including the exercise of stock options, can be unpredictable and can significantly impact our net earnings, net earnings per diluted share, and effective tax rate. These amounts represent the discrete tax expense recorded as excess tax expense for stock-based compensation.

Full text with the tables
                                                                                
  Exhibit 99.1                                                                  
                                                                                
           Inspire Medical Systems, Inc. Announces Third Quarter 2026           
                                                                                
                               Financial Results                                
                                                                                
                                                                                
  •                                                                             
                                                                                
Third quarter revenue of $206.7 million
                                                                                
  •                                                                             
                                                                                
Third quarter diluted EPS of $(0.84); adjusted diluted EPS of $0.14
                                                                                
  •                                                                             
                                                                                
Third quarter operating cash flow of $46.4 million

• AMA CPT® Editorial Panel approved new Category I CPT codes for single lead
hypoglossal nerve stimulation, including Inspire V, set to take effect January
1, 2028
                                                                                
  MINNEAPOLIS, MN - November 2, 2026                                            
                                                                                
- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the Company), a
medical technology company focused on the development and commercialization of
innovative, minimally invasive solutions for patients with obstructive sleep
apnea, today reported financial results for the quarter ended September 30,
2026.

“We are pleased to have delivered sequential growth in the third quarter, with
U.S. performance coming in ahead of our expectations. Results suggest that,
despite some lingering headwinds, there is greater comfort among implanting
physicians with the current coding dynamic. We will stay disciplined in our
education initiatives and focused on executing our strategic priorities as we
finish out 2026 and plan for a return to growth in 2027,” said Tim Herbert,
Chairman and CEO of Inspire Medical Systems.

“Looking further ahead, we were also pleased with the AMA Editorial Panel’s
September approval of a new CPT® code for single lead HGNS devices, including
the Inspire V system. When this takes effect in January 2028, a dedicated code
set will give physicians and hospitals enhanced clarity around coding and
reimbursement and, in turn, further enable patient access to Inspire therapy.
With that progress, and the investment capacity we’re redirecting into high-
impact revenue growth initiatives through Project Horizon, we believe we are
positioned well for growth in the years ahead.”

Third Quarter 2026 Financial Results (Third Quarter 2026 compared to Third
Quarter 2025)

• Revenue decreased 7.9% to $206.7 million, driven primarily by a decline in
U.S. revenue. The U.S. revenue decline was primarily driven by the adverse
impacts of coding and reimbursement challenges.

• Gross margin increased 20 bps to 86.0%, primarily due to increased sales mix
of the Inspire V system, which has a higher gross margin than the Inspire IV
system.

• Operating expenses increased $23.5 million, or 12.8%, to $206.6 million,
primarily due to $24.1 million of restructuring charges, legal settlement
expense of $7.0 million, and higher legal fees, partially offset by lower
marketing expenses and lower stock-based compensation expense.

• Operating loss was $28.7 million, and operating margin was (13.9)%. Adjusted
operating income was $1.9 million, and adjusted operating margin was 0.9%.

• The effective tax rate was 2.5% compared to 26.7%. The decrease in the
effective tax rate was primarily driven by the current period pre-tax loss and
discrete tax charges related to restructuring. For the three months ended
September 30, 2025, the Company maintained a full valuation allowance against
federal and state deferred tax assets, which was subsequently released at
December 31, 2025.

• Net loss was $24.4 million and adjusted net earnings was $4.1 million.

• Diluted EPS was $(0.84) and adjusted diluted EPS was $0.14.
                                                                                
  Financial Condition                                                           
                                                                                
• Net cash provided by operating activities for the three months ended September
30, 2026 was $46.4 million, compared to $68.5 million in the prior year period.
The change was primarily driven by lower net earnings and lower collections on
receivables due to the third quarter 2025 cash recovery following temporary
issues with the implementation of a new invoice portal and delivery process in
the second quarter of 2025.

• As of September 30, 2026, cash, cash equivalents, and investments increased
$48.5 million to $453.1 million as compared to December 31, 2025.
                                                                                
  Full Year 2026 Guidance                                                       
                                                                                
The Company is narrowing its previously announced revenue outlook to be in the
range of $850 million to $860 million, compared to the previous range of $835
million to $875 million. Additionally, the Company now expects adjusted
operating margin to be in the range of 4.5% to 5.5%, diluted EPS to be in the
range of $(0.36) to $(0.10) and adjusted diluted EPS to be in the range of $1.20
to $1.40.

The Company’s outlook assumes an effective tax rate of approximately 120% to
175% and an adjusted effective tax rate of 33% to 34%, estimated weighted
average diluted shares outstanding of approximately 28.9 million, and capital
expenditures between $35 million to $40 million.
                                                                                
  Webcast and Conference Call                                                   
                                                                                
The Company's management will host a conference call after market close today,
Monday, November 2, 2026, at 5:00 p.m. Eastern Time to discuss these results and
answer questions.

To access the conference call, please preregister on

https://register-conf.media-
server.com/register/BI4b0290b4bb464cecaa0a2b420ca13a02 .

Registrants will receive confirmation with dial-in details.

A live webcast of the event can be accessed on https://edge.media-
server.com/mmc/p/d84s2zzb/ . A replay of the webcast will be available on
https://investors.inspiresleep.com starting approximately two hours after the
event and archived on the site for two weeks.
                                                                                
  About Inspire Medical Systems                                                 
                                                                                
Inspire Medical Systems is a medical technology company focused on the
development and commercialization of innovative, minimally invasive solutions
for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy
is the first FDA, EU MDR, and PDMA-approved neurostimulation technology that
provides a safe and effective treatment for moderate to severe obstructive sleep
apnea.

For additional information about Inspire, please visit www.inspiresleep.com .
                                                                                
  Use of Non-GAAP Financial Measures                                            
                                                                                
This press release includes non-GAAP financial measures, including without
limitation, adjusted operating income, adjusted operating margin, adjusted
earnings before income taxes, adjusted income tax expense, adjusted effective
tax rate, adjusted net earnings, adjusted net earnings per diluted share
("EPS"), adjusted EBITDA, and adjusted EBITDA margin, which differ from
financial measures calculated in accordance with U.S. generally accepted
accounting principles (“GAAP”).

We define adjusted operating income as operating income or loss adjusted for
items that are not indicative of our ongoing operations. Operating income is the
most directly comparable GAAP financial measure to adjusted operating income. We
define adjusted operating margin in this release as adjusted operating income
divided by revenue. Operating margin is the most directly comparable GAAP
financial measure to adjusted operating margin. Adjusted earnings before income
taxes is defined as earnings before income taxes, adjusted for items that are
not

indicative of our ongoing operations. Earnings before income taxes is the most
directly comparable GAAP financial measure. Adjusted income tax expense is
defined as income tax expense, adjusted for items that are not indicative of our
ongoing operations. Adjusted effective tax rate is adjusted income tax expense
divided by adjusted earnings before income taxes. Income tax expense is the most
directly comparable GAAP financial measure. Adjusted net earnings is defined as
net earnings or loss, adjusted for items that are not indicative of our ongoing
operations. Net earnings or loss is the most directly comparable GAAP financial
measure to adjusted net earnings. Adjusted net earnings per diluted share is
calculated as adjusted net earnings divided by the diluted weighted average
shares outstanding. Net earnings or loss per diluted share is the most directly
comparable GAAP financial measure to adjusted net earnings per diluted share. We
define adjusted EBITDA as net earnings or loss, less interest and dividend
income, net, plus income tax expense, plus depreciation and amortization, plus
stock-based compensation expense, adjusted for items that are not indicative of
our ongoing operations. Net earnings or loss is the most directly comparable
GAAP financial measure to adjusted EBITDA. We define adjusted EBITDA margin in
this release as adjusted EBITDA divided by revenue. Net earnings or loss margin
is the most directly comparable GAAP measure to adjusted EBITDA margin.
Reconciliations of these non-GAAP financial measures to their most directly
comparable GAAP measures are included in this press release.

These non-GAAP financial measures are presented because we believe they are
useful indicators of our operating performance and facilitate a more meaningful
trend analysis without the distortion of various adjustment items. Management
uses these measures principally as measures of our underlying operating
performance, trends, and for planning purposes, including the preparation of our
annual operating plan and financial projections. We believe these measures are
useful to investors as supplemental information and because they are frequently
used by analysts, investors, and other interested parties to evaluate companies
in our industry. We also believe these non-GAAP financial measures are useful to
our management and investors as a measure of comparative operating performance
from period to period.

These non-GAAP financial measures should not be considered as an alternative to,
or superior to, the most directly comparable GAAP financial measures, as
measures of financial performance or cash flows from operations, as a measure of
liquidity, or any other performance measure derived in accordance with GAAP, and
they should not be construed to imply that our future results will be unaffected
by unusual or non-recurring items. In addition, Adjusted EBITDA is not intended
to be a measure of cash flow for management’s discretionary use, as it does not
reflect certain cash requirements such as tax payments, capital expenditures,
and certain other cash costs that may recur in the future. Adjusted EBITDA
contains certain other limitations, including the failure to reflect our cash
expenditures, cash requirements for working capital needs, and cash costs to
replace assets being depreciated and amortized. In evaluating our non-GAAP
financial measures, you should be aware that in the future we may incur expenses
that are the same as or similar to some of the adjustments in this presentation.
Our presentation of non-GAAP financial measures should not be construed to imply
that our future results will be unaffected by any such adjustments. Management
compensates for these limitations by primarily relying on our GAAP results in
addition to using non-GAAP financial measures on a supplemental basis. These
measures and their definitions are discussed in more detail below and our
definition of these non-GAAP financial measures is not necessarily comparable to
other similarly titled captions of other companies due to different methods of
calculation.
                                                                                
  Forward Looking Statements                                                    
                                                                                
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements other than
statements of historical facts are forward-looking statements, including,
without limitation, statements regarding estimated financial and non-financial
impacts from our strategic growth plan (including without limitation , the
extent and manner of the use of investments in revenue growth initiatives as
well as the time to complete the strategic growth plan) and potential impacts to
our business (including potential actions and solutions, such as the new
Category I CPT code for Inspire V set to take effect January 1, 2028 and final
2027 Medicare reimbursement payments, as well as timing of these impacts and any
related clarity) associated with coding and reimbursement, and our expectations
regarding our future growth prospects and full year 2026 financial outlook
(including without limitation expectations for the impacts of coding and
reimbursement, revenue, expected growth, adjusted operating margin, net earnings
or loss per diluted share, adjusted net earnings per diluted share, effective
tax rate, adjusted effective tax rate, weighted average diluted shares
outstanding and capital expenditures). In some cases, you can identify forward-
looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’
‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ “future,” “outlook,” “guidance,”
‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’
‘‘predict,’’ ‘‘potential,’’ ‘‘continue,’’ or the negative of these terms or
other similar expressions, although not all forward-looking statements contain
these words.

These forward-looking statements are based on management’s current expectations
and involve known and unknown risks and uncertainties that may cause our actual
results, performance, or achievements to be materially different from any future
results, performance, or achievements expressed or implied by the forward-
looking statements. Such risks and uncertainties include, among others: our
dependency on our Inspire system for revenues; fluctuations in our financial
results and the market price of our common stock; our ability to sustain or
increase our profitability and our history of operating losses; commercial
success and market acceptance of our Inspire therapy; our ability to achieve and
maintain adequate and clear levels of coverage or reimbursement for our Inspire
system or any future products we may seek to commercialize; competitive
companies, technologies, and pharmaceuticals in our industry; our ability to
expand our indications and develop and commercialize additional products and
enhancements to our Inspire system; our ability to forecast demand and manage
our inventory; our dependence on third-parties; risks related to consolidation
in the healthcare industry; our ability to expand, manage, and maintain our
direct sales and marketing organization, and to market and sell our Inspire
system in markets outside of the United States; our ability to manage our
growth; risks related to product liability claims and warranty claims; our
ability to address quality issues that may arise with our Inspire system; any
failure of key information technology systems, processes, or sites or damage to
or inability to access our physical facilities; any violations of anti-bribery,
anti-corruption, and anti-money laundering laws; future needs for additional
financing; risks related to our tax assets and changes in tax laws; our ability
to timely commercialize or obtain regulatory approvals or certifications for our
Inspire therapy and system; U.S. Food and Drug Administration (FDA) or other
United States or foreign regulatory actions affecting us or the healthcare
industry generally; our ability to establish and maintain intellectual property
protection for our Inspire therapy and system or avoid claims of infringement;
and our strategic growth plan may not achieve our intended outcome.

Other important factors that could cause actual results, performance or
achievements to differ materially from those contemplated in this press release
can be found under the captions “Risk Factors” and "Management's Discussion and
Analysis of Financial Condition and Results of Operations“ in our Annual Report
on Form 10-K for the fiscal year ended December 31, 2025, our Quarterly Report
on Form 10-Q for the quarter ended June 30, 2026, and as such factors may be
updated from time to time in our other filings with the SEC, which are
accessible on the SEC’s website at www.sec.gov and the Investors page of our
website at www.inspiresleep.com. These and other important factors could cause
actual results to differ materially from those indicated by the forward-looking
statements made in this press release. Any such forward-looking statements
represent management’s estimates as of the date of this press release. While we
may elect to update such forward-looking statements at some point in the future,
unless required by applicable law, we disclaim any obligation to do so, even if
subsequent events cause our views to change. Thus, one should not assume that
our silence over time means that actual events are bearing out as expressed or
implied in such forward-looking statements. These forward-looking statements
should not be relied upon as representing our views as of any date after the
date of this press release.
                                                                                
  Investor and Media Contact                                                    
                                                                                
Brian Johnston or Louisa Smith

Gilmartin Group

[email protected]
                                                                                
                         Inspire Medical Systems, Inc.                          
                                                                                
                                                                                
               Consolidated Statements of Operations (unaudited)                
                                                                                
               (in thousands, except share and per share amounts)               
                                                                                
           Three                              Nine                              
           Months                             Months                            
           Ended   Septem…                    Ended    Septe…                   
           2026        30,    2025            2026        30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Reve…    $       206,695    $     224,5…    $        611,8…    $     642,904  
  Cost                                                                          
  of                28,837          31,773             85,630           97,154  
  goods                                                                         
  sold                                                                          
  Gross            177,858          192,7…             526,2…          545,750  
  prof…                                                                         
  Oper…                                                                         
  expe…                                                                         
  Rese…                                                                         
  and               22,176          24,211             72,700           78,223  
  deve…                                                                         
  Sell…                                                                         
  gene…            184,398          158,8…             483,8…          462,684  
  and                                                                           
  admi…                                                                         
  Total                                                                         
  oper…            206,574          183,0…             556,5…          540,907  
  expe…                                                                         
  Oper…                                                                         
  (los…            -28,716           9,644             -30,3…            4,843  
  inco…                                                                         
  Inte…                                                                         
  and                                                                           
  divi…             -3,897          -3,973             -11,3…          -13,521  
  (inc…                                                                         
  net                                                                           
  Other                                                                         
  expe…                191              66                527            2,986  
  net                                                                           
  (Los…                                                                         
  earn…                                                                         
  befo…            -25,010          13,551             -19,4…           15,378  
  inco…                                                                         
  taxes                                                                         
  Inco…                                                                         
  tax                 -616           3,619             15,876            6,046  
  (ben…                                                                         
  expe…                                                                         
  Net                                                                           
  (los…    $       -24,394    $      9,932    $        -35,3…    $       9,332  
  earn…                                                                         
  Basic                                                                         
  (los…                                                                         
  earn…    $         -0.84    $       0.34    $         -1.23    $        0.32  
  per                                                                           
  share                                                                         
  Dilu…                                                                         
  (los…                                                                         
  earn…    $         -0.84    $       0.34    $         -1.23    $        0.31  
  per                                                                           
  share                                                                         
  Weig…                                                                         
  aver…                                                                         
  shar…                                                                         
  outs…                                                                         
  Basic            28,929…          29,33…             28,82…          29,512…  
  Dilu…            28,929…          29,60…             28,82…          29,938…  
                                                                                
                                                                                
                         Inspire Medical Systems, Inc.                          
                                                                                
                                                                                
                    Consolidated Balance Sheets (unaudited)                     
                                                                                
               (in thousands, except share and per share amounts)               
                                                                                
                                         September 30,                          
                                                  2026       December 31, 2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Assets                                                                        
  Current assets:                                                               
  Cash and cash equivalents           $        190,803    $            104,813  
  Investments, short-term                      137,168                 203,455  
  Accounts receivable, net of                                                   
  allowance                                                                     
  for credit losses of $787 and                104,706                 119,692  
  $1,080,                                                                       
  respectively                                                                  
  Inventories, net                             178,960                 145,293  
  Prepaid expenses and other                                                    
  current                                       15,988                  10,399  
  assets                                                                        
  Total current assets                         627,625                 583,652  
  Investments, long-term                       125,125                  96,330  
  Property and equipment, net                   85,635                  97,872  
  Operating lease right-of-use                  22,125                  23,532  
  assets                                                                        
  Deferred tax assets                           74,196                  88,667  
  Other non-current assets                      18,327                  17,264  
  Total assets                        $        953,033    $            907,317  
  Liabilities and stockholders'                                                 
  equity                                                                        
  Current liabilities:                                                          
  Accounts payable                    $         38,073    $             36,565  
  Accrued expenses                              59,265                  59,490  
  Total current liabilities                     97,338                  96,055  
  Operating lease liabilities,                                                  
  non-current                                   28,611                  29,998  
  portion                                                                       
  Other non-current liabilities                    135                     104  
  Total liabilities                            126,084                 126,157  
  Stockholders' equity:                                                         
  Preferred Stock, $0.001 par                                                   
  value;                                                                        
  10,000,000 shares authorized; no                   —                       —  
  shares                                                                        
  issued and outstanding                                                        
  Common Stock, $0.001 par value;                                               
  200,000,000 shares authorized;                                                
  28,941,555 and 28,579,015 issued                                              
  and                                               29                      29  
  outstanding at September 30,                                                  
  2026 and                                                                      
  December 31, 2025, respectively                                               
  Additional paid-in capital                 1,010,235                 927,159  
  Accumulated other comprehensive                                               
  (loss)                                        -1,449                     464  
  income                                                                        
  Accumulated deficit                         -181,866                -146,492  
  Total stockholders' equity                   826,949                 781,160  
  Total liabilities and                                                         
  stockholders'                       $        953,033    $            907,317  
  equity                                                                        
                                                                                
                                                                                
                         Inspire Medical Systems, Inc.                          
                                                                                
                                                                                
                  GAAP to Non-GAAP Reconciliations (unaudited)                  
                                                                                
                    (in thousands, except per share amounts)                    
                                                                                
      …                                                                         
      …                                                                         
      …                                                                         
      …                                                                         
      …                                                                         
      …                                                                         
 ────────────────────────────────────────────────────────────────────────────── 
      …       …      …      …                                       …      …    
      …       …      …      …                                       …      …    
                     …                                              …           
      $  …    $      $           %      …      …      …      …      $      $    
                                                                                
         —                       %      —      …      …                         
         —                       %      —      …      …                         
         —                       %      —      …      …                         
         —                       %      —      …      …                         
         —                       %      —      —      …                         
      $  …    $      $           %      …      …      …      …      $      $    
                                                                                
                                                                                
      …                                                                         
      …                                                                         
      …                                                                         
      …                                                                         
      …                                                                         
      …                                                                         
 ────────────────────────────────────────────────────────────────────────────── 
      …       …      …      …                                       …      …    
      …       …      …      …                                       …      …    
      $  …    $      $           %      …      …      …      …      $      $    
                                                                                
         —                       %      —      …      …                         
      $  …    $      $           %      …      …      …      …      $      $    
                                                                                
1 These costs represent legal-related expenses related to (a) a civil
investigative demand from the Department of Justice, (b) a patent infringement
suit that we filed against Nyxoah S.A. and its wholly-owned subsidiary, Nyxoah,
Inc. ("Nyxoah"), and (c) a patent infringement suit brought against us by
Nyxoah.

2 Legal settlement expense associated with the proposed settlement of a pixel-
tracking class action.

3 Restructuring charges related to Project Horizon.

4 Stock-based compensation expense benefit due to share forfeitures related to
actions of Project Horizon.

5 The accounting standards codification guidance governing employee stock-based
compensation requires that any excess or deficient tax deduction for stock-based
compensation be immediately recorded within income tax expense. Employee stock-
based compensation activity, including the exercise of stock options, can be
unpredictable and can significantly impact our net earnings, net earnings per
diluted share, and effective tax rate. These amounts represent the discrete tax
expense recorded as excess tax expense for stock-based compensation.
                                                                                
                         Inspire Medical Systems, Inc.                          
                                                                                
                                                                                
                  GAAP to Non-GAAP Reconciliations (unaudited)                  
                                                                                
                    (in thousands, except per share amounts)                    
                                                                                
      …                                                                         
      …                                                                         
      …                                                                         
      …                                                                         
      …                                                                         
      …                                                                         
 ────────────────────────────────────────────────────────────────────────────── 
      …       …      …      …                                       …      …    
      …       …      …      …                                       …      …    
                     …                                              …           
      $  …    $      $           %      …      …      …      …      $      $    
                                                                                
         —                       %      —      …      …                         
         —                       %      —      …      …                         
         —                       %      —      …      …                         
         —                       %      —      …      …                         
         —                       %      —      —      …                         
      $  …    $      $           %      …      …      …      …      $      $    
                                                                                
                                                                                
      …                                                                         
      …                                                                         
      …                                                                         
      …                                                                         
      …                                                                         
      …                                                                         
 ────────────────────────────────────────────────────────────────────────────── 
      …       …      …      …                                       …      …    
      …       …      …      …                                       …      …    
      $  …    $      $           %      …      …      …      …      $      $    
                                                                                
         —                       %      —      …      …                         
         —                       %      —      …      …                         
         —                       %      …      …      —                         
      $  …    $      $           %      …      …      …      …      $      $    
                                                                                
1 These costs represent legal-related expenses related to (a) a civil
investigative demand from the Department of Justice, (b) a patent infringement
suit that we filed against Nyxoah S.A. and its wholly-owned subsidiary, Nyxoah,
Inc. ("Nyxoah"), and (c) a patent infringement suit brought against us by
Nyxoah.

2 Legal settlement expense associated with the proposed settlement of a pixel-
tracking class action.

3 Restructuring charges related to Project Horizon.

4 Stock-based compensation expense benefit due to share forfeitures related to
actions of Project Horizon.

5 The accounting standards codification guidance governing employee stock-based
compensation requires that any excess or deficient tax deduction for stock-based
compensation be immediately recorded within income tax expense. Employee stock-
based compensation activity, including the exercise of stock options, can be

unpredictable and can significantly impact our net earnings, net earnings per
diluted share, and effective tax rate. These amounts represent the discrete tax
expense recorded as excess tax expense for stock-based compensation.

6 Represents accelerated stock-based compensation expense for certain employees
who were retirement eligible in accordance with the implementation of changes to
the treatment of equity awards under the Inspire Medical Systems, Inc. 2018
Incentive Award Plan upon the holder's death, disability, or retirement.

7 Represents a non-cash impairment of a strategic investment.
     Reconciliation of GAAP Net (Loss) Earnings to Non-GAAP Adjusted EBITDA     
                                                                                
            Three                              Nine                             
            Months                             Months                           
            Ended   Septem…                    Ended   Septem…                  
            2026        30,    2025            2026        30,    2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  (loss)    $       -24,394    $      9,932    $       -35,374    $      9,332  
  earni…                                                                        
  Inter…                                                                        
  and                                                                           
  divid…             -3,897          -3,973            -11,377          -13,5…  
  incom…                                                                        
  net                                                                           
  Income                                                                        
  tax                  -616           3,619             15,876           6,046  
  expen…                                                                        
  Depre…                                                                        
  and                 5,140           3,677             14,847          10,135  
  amort…                                                                        
  EBITDA            -23,767          13,255            -16,028          11,992  
  Stock…                                                                        
  compe…             26,917          29,468             88,832          102,2…  
  expen…                                                                        
  Legal               3,567           1,289              8,700           3,025  
  fees2                                                                         
  Legal               7,000               —              7,000               —  
  settl…                                                                        
  Restr…             24,138               —             24,138               —  
  charg…                                                                        
  Asset                                                                         
  impai…                  —               —                  —           4,046  
  charg…                                                                        
  Adjus…    $        37,855    $     44,012    $       112,642    $     121,3…  
  EBITDA                                                                        
                                                                                
1 Total stock-based compensation expense.

2 These costs represent legal-related expenses related to (a) a civil
investigative demand from the Department of Justice, (b) a patent infringement
suit that we filed against Nyxoah S.A. and its wholly-owned subsidiary, Nyxoah,
Inc. ("Nyxoah"), and (c) a patent infringement suit brought against us by
Nyxoah.

3 Legal settlement expense associated with the proposed settlement of a pixel-
tracking class action.

4 Restructuring charges related to Project Horizon.

5 Represents a non-cash impairment of a strategic investment.
 Reconciliation of GAAP Net (Loss) Earnings Margin and Non-GAAP Adjusted EBITDA 
                                     Margin                                     
                                                                                
          Three                                 Nine                            
          Mont…                               Months                            
          Ended                                Ended                            
          Sept…                               Septe…                            
            30,                                  30,                            
           2026              2025               2026             2025           
  Net                                                                           
  (lo…           -11.8  %           4.5  %            -5.8  %           1.5  %  
  ear…                                                                          
  mar…                                                                          
  Int…                                                                          
  and                                                                           
  div…            -1.9  %          -1.8  %            -1.9  %          -2.1  %  
  inc…                                                                          
  net                                                                           
  Inc…                                                                          
  tax             -0.3  %           1.6  %             2.6  %           0.9  %  
  exp…                                                                          
  Dep…                                                                          
  and              2.5  %           1.6  %             2.4  %           1.6  %  
  amo…                                                                          
  Sto…                                                                          
  com…            13.0  %          13.1  %            14.7  %          15.9  %  
  exp…                                                                          
  Leg…             1.7  %           0.6  %             1.4  %           0.5  %  
  fee…                                                                          
  Leg…             3.4  %             —  %             1.1  %             —  %  
  set…                                                                          
  Res…            11.7  %             —  %             3.9  %             —  %  
  cha…                                                                          
  Ass…                                                                          
  imp…               —  %             —  %               —  %           0.6  %  
  cha…                                                                          
  Adj…                                                                          
  EBI…            18.3  %          19.6  %            18.4  %          18.9  %  
  mar…                                                                          
                                                                                
1 Net (loss) earnings margin is calculated as net (loss) earnings divided by
total revenue.

2 Total stock-based compensation expense.

3 These costs represent legal-related expenses related to (a) a civil
investigative demand from the Department of Justice, (b) a patent infringement
suit that we filed against Nyxoah S.A. and its wholly-owned subsidiary, Nyxoah,
Inc. ("Nyxoah"), and (c) a patent infringement suit brought against us by
Nyxoah.

4 Legal settlement expense associated with the proposed settlement of a pixel-
tracking class action.

5 Restructuring charges related to Project Horizon.

6 Represents a non-cash impairment of a strategic investment.

7 Adjusted EBITDA margin is calculated as Adjusted EBITDA divided by total
revenue.
                                                                                
                             Full Year 2026 Outlook                             
                                                                                
 Reconciliation of Full Year 2026 Outlook of Estimated Net (Loss) Earnings per  
                                 Diluted Share                                  
                                                                                
                   to Adjusted Net Earnings per Diluted Share                   
                                                                                
                                                                                
                     Outlook Full                  Tax Rate                     
                        Year 2026                  Outlook Full                 
                                                   Year 2026                    
                        Low Range    High Range    Low Range        High Range  
  Net (loss)                                                                    
  per diluted             $(0.36)       $(0.10)    175.0%           120.0%      
  share                                                                         
  Legal fees1                0.31          0.29                                 
  Legal                      0.18          0.18                                 
  settlement2                                                                   
  Restructuring              0.64          0.64                                 
  charges3                                                                      
  Share                     -0.16         -0.16                                 
  forfeitures4                                                                  
  Tax impact of                                                                 
  stock-based                0.59          0.55                                 
  compensation5                                                                 
  Adjusted net                                                                  
  earnings per              $1.20         $1.40    34.0%            33.0%       
  diluted share                                                                 
                                                                                
1 These costs represent legal-related expenses related to (a) a civil
investigative demand from the Department of Justice, (b) a patent infringement
suit that we filed against Nyxoah S.A. and its wholly-owned subsidiary, Nyxoah,
Inc. ("Nyxoah"), and (c) a patent infringement suit brought against us by
Nyxoah.

2 Legal settlement expense associated with the proposed settlement of a pixel-
tracking class action.

3 Restructuring charges related to Project Horizon.

4 Stock-based compensation expense benefit due to share forfeitures related to
actions of Project Horizon.

5 The accounting standards codification guidance governing employee stock-based
compensation requires that any excess or deficient tax deduction for stock-based
compensation be immediately recorded within income tax expense. Employee stock-
based compensation activity, including the exercise of stock options, can be
unpredictable and can significantly impact our net earnings, net earnings per
diluted share, and effective tax rate. These amounts represent the discrete tax
expense recorded as excess tax expense for stock-based compensation.

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/INSP/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.